This Article Full Text Full Text (PDF) CME: Take the course for this article: Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Treat, J. Articles by Levin, J. Search for Related Content PubMed PubMed Citation Articles by Treat, J. Articles by Levin, J.

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

^a Fox Chase-Temple University Cancer Center, Philadelphia, Pennsylvania, USA; ^b GlaxoSmithKline, Philadelphia, Pennsylvania, USA

Correspondence: Joseph Treat, M.D., Fox Chase-Temple University Cancer Center, 3322 North Broad Street, Philadelphia, Pennsylvania 19140, USA. Telephone: 215-707-2777; Fax: 215-707-8092; e-mail: treatja{at}tuhs.temple.edu

Topotecan is the only single-agent therapy approved by the U.S. Food and Drug Administration for the treatment of patients with recurrent small cell lung cancer (SCLC). Poor performance status (PS) at the time of relapse can hinder the ability of a patient to tolerate second-line chemotherapy. To investigate the feasibility of topotecan in the treatment of relapsed SCLC patients with PS 2 scores, we retrospectively analyzed data from five clinical trials that included 479 patients who were treated with single-agent topotecan at a dose of 1.5 mg/m²/day on days 1–5 of a 21-day course. Of these patients, 381 had a PS 0 or 1 and 98 had a PS 2. Topotecan was well tolerated by both patient groups. Hematologic toxicities were generally manageable, and neutropenia was noncumulative. With the exception of grade 3/4 anemia, the incidences of severe hematologic toxicities were not statistically different between the two groups. The nonhematologic toxicity profiles were also similar in the two patient groups. Treatment provided similar benefits, including antitumor response rates and symptom palliation, in PS 0/1 and PS 2 patients. As expected, the median overall survival time was shorter in patients with worse PS scores; the median overall survival times were 36.3 weeks, 25.4 weeks, and 16 weeks for PS 0, PS 1, and PS 2 patients, respectively. In conclusion, treatment with topotecan is feasible and well tolerated in patients with relapsed SCLC with suboptimal PS scores.

Key Words. Lung neoplasms • Palliative care • Salvage therapy • Topotecan

This article has been cited by other articles:

				S. Miknyoczki, H. Chang, J. Grobelny, S. Pritchard, C. Worrell, N. McGann, M. Ator, J. Husten, J. Deibold, R. Hudkins, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity Mol. Cancer Ther., August 1, 2007; 6(8): 2290 - 2302. [Abstract] [Full Text] [PDF]

				J. R. Eckardt, J. von Pawel, Z. Papai, A. Tomova, V. Tzekova, T. E. Crofts, S. Brannon, P. Wissel, and G. Ross Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2044 - 2051. [Abstract] [Full Text] [PDF]

				A. Ardizzoni Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update Oncologist, December 1, 2004; 9(suppl_6): 4 - 13. [Abstract] [Full Text] [PDF]

				R. J. Gralla Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life Oncologist, December 1, 2004; 9(suppl_6): 14 - 24. [Abstract] [Full Text] [PDF]